Amlodipine and valsartan as components of a rational and effective fixed-dose combination. by Waeber, B. & Ruilope, L.M.
© 2009 Waeber and Ruilope, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 165–174 165
R E V I E W
Amlodipine and valsartan as components
of a rational and effective fi xed-dose combination
Bernard Waeber1
Luis M Ruilope2
1Division of Clinical Pathophysiology, 
University Hospital, Faculty of Biology 
and Medicine, University of Lausanne, 
Switzerland; 2Hypertension Unit, 
Hospital 12 de Octubre, Madrid, Spain
Correspondence: CHUV, Prof. Bernard 
Waeber 
Division of Clinical Pathophysiology, 
PPA MP 14/204, CH-1011 Lausanne, 
Switzerland
Tel +41 21 314 0760
Fax +41 21 314 2518
Email bernard.waeber@chuv.ch
Abstract: Pharmacological treatment of hypertension is effective in preventing cardiovascular 
and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are 
widely used today to initiate antihypertensive therapy but, when given as monotherapy, do 
not sufﬁ ce in most patients to normalize blood pressure. Combining the two types of agents 
considerably increases the antihypertensive efﬁ cacy, but not at the expense of a deterioration 
of tolerability. This is exempliﬁ ed by the experience accumulated with the recently developed 
ﬁ xed dose combination containing the AT
1
-receptor blocker valsartan (160 mg) and the dihy-
dropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized 
blood pressure (140/90 mmHg) within 8 weeks in a large fraction of hypertensive patients 
(78.4% and 85.2% using the 5/160 [n = 371] and 10/160 mg [n = 377] dosage, respectively). 
Like all AT
1
-receptor blockers valsartan has a placebo-like tolerability. Valsartan prevents to a 
large extent the occurrence amlodipine-induced peripheral edema. Both amlodipine and valsartan 
have beneﬁ cial effects on cardiovascular morbidity and mortality, as well as protective effects 
on renal function. The co-administration of these two agents is therefore very attractive, as it 
enables a rapid and sustained blood pressure control in hypertensive patients. The availability of 
a ﬁ xed-dose combination based on amlodipine and valsartan is expected therefore to facilitate 
the management of hypertension, to improve long-term adherence with antihypertensive therapy 
and, ultimately, to have a positive impact on cardiovascular and renal outcomes.
Keywords: antihypertensive therapy, ﬁ xed-dose combination, calcium antagonists, angiotensin 
receptor blockers, blood pressure control, tolerability
Introduction
Hypertension has long been recognized as a major independent risk factor for cardiovascular 
and renal diseases and still represents worldwide a leading cause of mortality, both in 
industrialized and developing countries.1,2 Pharmacological treatment of hypertension is 
very effective in protecting against complications such as stroke, myocardial infarction, 
heart failure and deterioration of renal function.3–5 Calcium antagonists (CAs) and blockers 
of the renin-angiotensin system, in particular angiotensin converting enzyme inhibitors 
(ACE-Is) and angiotensin II receptor blockers (ARBs), are widely used antihypertensive 
drugs with well documented beneﬁ cial effects, as shown repeatedly in individual trials and 
meta-analysis.3–5 This led international experts to consider these classes of blood pressure-
lowering agents as valuable options to initiate antihypertensive therapy.6 It is recognized, 
however, that any antihypertensive drug, regardless of its mechanism of action, allows 
blood pressure normalization in only a fraction of patients, so that combination therapy is 
required in most patients to achieve strict blood pressure control.6,7 The co-administration 
in a single tablet of  2 drugs acting on different pressor systems permits at the same time to 
improve the blood pressure control rate and to simplify the treatment, thereby facilitating 
the long-term adherence with therapy.8,9 No wonder therefore that the interest for ﬁ xed-
dose combinations in the ﬁ eld of hypertension is growing rapidly.
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Amlodipine (dihydropyridine CA) and valsartan (ARB) 
have been evaluated in numerous interventional trials and 
have become very popular in the management of hypertensive 
patients.3–5 A ﬁ xed-dose combination containing amlodipine 
and valsartan has been recently developed.10 The present 
paper reviews the rationale for co-administering these two 
agents, drawing on the experience accumulated so far with 
this new drug combination.
Amlodipine and valsartan: two 
antihypertensive agents with 
different mechanisms of action
CAs have been extensively studied during the last 3 decades 
and have emerged as a major advance in the management of 
diverse cardiovascular diseases, including hypertension. CAs 
represent a heterogeneous group of agents.11,12 They all block 
the transmembrane calcium inﬂ ux in vascular and myocardial 
cells through L-type channels, being more or less selective 
for the vasculature and the heart. Dihydropyridines have the 
most potent vasodilatory effects, with no overt cardiac effects 
in humans. Amlodipine is a dihydropyridine characterized 
by a slow onset and a long duration:13 maximal plasma con-
centrations are not achieved until about 6 hours after dosing 
and the elimination half-life exceeds 35 hours. The vasodila-
tion induced by calcium entry blockade may trigger a reﬂ ex 
increase in sympathetic nerve activity, possibly manifesting 
as a heart rate acceleration.14 If present, the hyperadrenergic 
state system might augment myocardial oxygen demand and 
be harmful in patients with coronary heart disease.15 Notably, 
no evidence for a sustained activation of the sympathetic 
drive has been found in hypertensive patients treated with 
long-acting dihydropyridines, amlodipine included.16
Valsartan, like all ARBs, acts by inhibiting the binding of 
angiotensin II to the AT
1
-subtype of angiotensin II receptor.17,18 
A hallmark of blockers of the renin-angiotensin system is 
their ability to lower blood pressure without usually induc-
ing a reﬂ ex increase in sympathetic nerve activity, which is 
reﬂ ected by the absence of consistent changes in heart rate.19,20 
After oral administration, the peak plasma concentration of 
valsartan is reached after 3 hours, and the elimination half-life 
is 6 hours. This compound has already been investigated in 
a hypertension outcome trial.21
The antihypertensive efﬁ cacy of CAs and ARBs is dose-
dependent. For tolerability, however, a clear-cut dose-dependency 
exists only for CAs.8 The commonest symptoms of CAs, ie, 
ﬂ ushing, ankle edema, headaches and palpitations, are caused 
by drug-induced vasodilation.14 The side-effects attributable 
to vasodilation are caused mainly by dihydropyridine 
derivatives. Headache, palpitations and ﬂ ushing occur most 
often during initiation of treatment, and are reduced in 
frequency and/or severity by compounds such as amlodipine 
exhibiting a slow onset of action and smooth peak versus 
trough blood levels, thus avoiding excessive blood pressure 
ﬂ uctuations during the day. Ankle edema encountered during 
calcium entry blockade is not due to renal ﬂ uid retention but 
involves a rise in intracapillary pressure (as a consequence 
of a selective diminution of the precapillary arteriolar tone), 
with an ensuing leak of ﬂ uid into the interstitium.22 Valsartan, 
like all ARBs, exhibits a placebo-like tolerability.8,17
Position of calcium antagonists 
and angiotensin receptor blockers 
in the treatment of hypertension
To date, all currently available long-acting CAs and ARBs 
are considered by many national and international authorities 
as a valuable ﬁ rst-line option for the management of hyper-
tension, for instance experts who prepared the most recent 
hypertension guidelines on behalf of the European Society of 
Hypertension (ESH) and the European Society of Cardiology 
(ESC).6 CAs and ARBs are generally equally effective 
in lowering blood pressure when compared in groups of 
unselected patients with mild to moderate hypertension. 
A given patient may, however, respond favorably to a CA, 
but not to an ARB, and vice versa. According to experts in 
UK, the age and the ethnicity may be helpful in guiding the 
choice of initial therapy:23 older patients and black patients 
of any age should receive preferably a CA, whereas younger 
patients are more likely to normalize their blood pressure 
using a blocker of the renin-angiotensin system, as renin 
secretion tends to decrease with aging. The magnitude of 
the blood pressure fall induced by antihypertensive drugs 
increases with the degree of hypertension, particularly when 
using vasodilators such as CAs.
There is ample evidence today that dihydropyridine 
CAs and ARBs have a positive impact on the cardiovas-
cular, cerebrovascular and renal outcomes of hypertensive 
patients.3–5 This is especially true in high risk patients with 
multiple cardiovascular risk factors, subclinical target organ 
damage, or established cardiovascular or renal disease. 
Amlodipine and valsartan were part of the drug regimens 
under study in several large hypertension morbidity–
mortality trials, and much of the present knowledge on 
the beneﬁ cial effects of CAs and ARBs in various clinical 
conditions associated with high blood pressure has been 
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accumulated using these two compounds. It is beyond the 
scope of this paper to review the evidence supporting the 
use of dihydropyridine CAs versus ARBs in the individual 
patient. Figure 1 summarizes only the principal indications 
of these agents as initial therapy, based on the most recent 
ESH/ESC recommendations.6 It appears that there are good 
reasons for using either a dihydropyridine or an ARB in the 
prevention and/or the treatment of most complications of 
hypertension. CAs antagonists and ARBs, including amlo-
dipine and valsartan, are easy to use and can be administered 
to nearly all hypertensive patients, which represents a major 
advantage in everyday practice. Notably, long-acting dihy-
dropyridines have no compelling contra-indication. ARBs 
should certainly not be given in pregnant women. They 
should be avoided or used only with close monitoring of 
renal function in patients with bilateral renal artery stenosis 
or a renal artery stenosis on a single kidney. In patients with 
unilateral renal artery stenosis, a drug regimen comprising 
a blocker of the renin-angiotensin system might, however, 
represent a valuable alternative to renal revascularization.24 
ARBs tend to increase plasma potassium levels and should 
not be used in patients with hyperkaliemia, and not be co-
administered with a potassium-sparing diuretic unless renal 
function is normal.
Rationale for combining amlodipine 
and valsartan
Dihydopyridines and ARBs have a major advantage: they 
can be administered safely with other classes of antihyper-
tensive drugs, including with each other. Combining 2 agents 
lowering blood pressure by different mechanisms allows a 
major gain in antihypertensive efﬁ cacy compared with mono-
therapies, but usually not at the expense of a deterioration of 
tolerability.8 Notably, the counter-regulatory response of the 
Figure 1 Conditions (indicated by arrows) favoring the use of dihydropyridine calcium antagonists and angiotensin receptor blockers according to the 2007 European 
Society of Hypertension/European Society of Hypertension Hypertension Recommendations.  Adapted with permission from Mancia et al. J Hypertens. 2007;25:1105–1187.6 
Copyright © 2007 Lippincott Williams & Wilkins.
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sympathetic nervous system to the vasodilation induced by 
dihydropyridines is buffered by concomitant blockade of the 
renin-angiotensin system, which may contribute to enhance-
ment of the blood pressure response as well as to prevention 
of the reﬂ ex increase in heart rate and the palpitations possibly 
occurring during calcium entry blockade.25 Also of note is 
that dihydropyridines, unlike selective arterial vasodilators, 
have a natriuretic effect, which is expected to render blood 
pressure maintenance more angiotensin II-dependent.26
Much experience has been accumulated with amlodipine 
and valsartan, both in clinical trials and in routine conditions 
of use, as the two drugs are now distributed worldwide.3–5 It 
was therefore appealing to have available a ﬁ xed-dose com-
bination containing these two agents with well-documented 
salutary effects.10 The appropriate doses of the two compo-
nents were established in 2 multicenter, 8-week, random-
ized, double-blind, placebo-controlled, trials.27 Both studies 
included a 2-week washout period, which was followed 
by a single-blind, placebo run-in period of 2 to 4 weeks, 
and thereafter by a 8-week, double-blind, active-treatment 
period (Study 1:amlodipine in daily doses of 2.5 to 5 mg, 
valsartan in daily doses of 40, 80, 160 or 320 mg, alone or in 
combination, or placebo; Study 2: amlodipine in a daily dose 
of 10 mg, valsartan in daily doses of 160 or 320 mg, alone or 
in combination, or placebo) .There were overall signiﬁ cantly 
greater blood pressure reductions with the combination regi-
mens compared with the individual components, and a posi-
tive dose-response was observed for all combinations. Table 1 
depicts the results obtained in the 2478 studied patients. There 
was a clear-cut dose-dependent blood pressure lowering effect 
of both monotherapies, and the co-administration of the two 
compounds was signiﬁ cantly more effective, whatever the 
dosages of the two combined agents, than equivalent doses 
of monotherapies. The analysis of the total safety population 
(n = 3155) showed no signiﬁ cant difference in the overall rate 
of adverse events between patients treated with amlodipine 
– valsartan (44.1%) and those having received amlodipine 
alone (45.7%), but was greater (p  0.05) in patients on the 
combination than in those on valsartan monotherapy (39.8%). 
The incidence of peripheral edema was lower (p  0.05) 
with amlodipine and valsartan given in combination (5.4%) 
than with amlodipine alone (8.7%), but higher (p  0.05) 
compared with valsartan monotherapy (2.1%). The rate of 
adverse events leading to discontinuation of the treatment 
was low in the amlodipine–valsartan groups (1.8%) and was 
comparable to that of placebo (2.1%). Headache was the 
second most frequent adverse event after peripheral edema. 
It was encountered less frequently (p  0.05) in patients 
on amlodipine–valsartan combination (4.3%) than in those 
administered amlodipine monotherapy (7.6%).
It is worth to discussing here in more detail the 
development of peripheral edema, a common and trouble-
some adverse effect of CAs.22 As already mentioned, the 
ﬂ uid retention occurring during treatment with these agents 
involves a rise in intracapillary pressure, as a consequence 
of a selective diminution of the precapillar tone, with an 
ensuing net leak of ﬂ uid into the interstitium. Blockers of 
the renin-angiotensin system attenuate this process, most 
likely because of their ability to dilate not only the arteriolar 
vascular bed, but also the venous capacitance vessels. This 
was proven by a study in which the ankle foot volume was 
assessed by the principle of water displacement in 130 hyper-
tensive patients randomized to receive for 6 weeks, according 
a cross-over design, either valsartan 160 mg/day, amlodipine 
10 mg/day, or a combination of the two.28 Amlodipine, but 
not valsartan, signiﬁ cantly increased ankle foot volume, the 
latter being, however, signiﬁ cantly smaller during the co-
administration of amlodipine and valsartan compared with 
amlodipine monotherapy.
Antihypertensive effi cacy and safety 
of amlodipine and valsartan 
as mono- or combination therapy 
in stage 2 hypertension and elderly 
hypertensive patients
As pointed out above, the co-administration of amlodipine 
and valsartan is more effective in lowering blood pres-
sure than the corresponding monotherapies. There is a 
need for such an increased efﬁ cacy especially in patients 
with blood pressure levels largely above the normal upper 
values, for example in those with stage 2 hypertension 
Table 1 Mean blood pressure reductions (mmHg) induced by an 
8-week once-daily, treatment with different doses of amlodipine 
and valsartan given alone or in combination. 
Amlodipine doses, mg
V
al
sa
rt
an
 d
os
es
, m
g 0 2.5 5
0 7.3/7.1 12.4/9.3 15.1/11.5
40 11.8/10.1 15.5*#/10.8 19.6*#/14.6*#
80 12.9/9.7 17.0*#/13.4*# 20.8*#/14.5*#
160 15.1/11.0 16.7#/13.3*# 19.5*#/14.2*#
320 15.7/13.4 18.3#/14.2*# 22.7*#/15.9*#
*p  0.05 versus the same dose of valsartan monotherapy.
#p  0.05 versus the same dose of amlodipine monotherapy.
Adapted with permission from Philipp et al. Clin Ther. 2007;29:563–580.27 Copyright 
© Elsevier.
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(systolic blood pressure 160 mmHg and/or diastolic 
blood pressure 100 mmHg). Actually, the use of com-
bination therapy is most often required in such patients to 
normalize blood pressure, so that ﬁ xed dose combinations 
are considered a valuable choice to initiate therapy in this 
subgroup of patients.6 The efﬁ cacy of amlodipine and valsar-
tan, alone as well as in combination, has been compared in 
patients with type 2 hypertension and in patients with type 1 
hypertension (systolic blood pressure of 140 to 159 mmHg 
and/or diastolic blood pressure of 90 to 99 mmHg).29 This 
was done by performing a post-hoc subgroup analysis of 
the two double-blind, randomized, placebo-controlled trials, 
that were similarly designed as already described above.27 
A total of 1355 and 1800 patients had stage 1 and stage 2 
hypertension, respectively. Baseline blood pressure averaged 
145.9/96.8 mmHg in the former, and 160.8/101.0 mmHg in 
the latter. In both trials, patients with stage 2 hypertension 
experienced greater reductions in systolic blood pressure 
than those with stage 1 hypertension. The maximum effects 
were obtained with the higher dose combinations in the two 
subgroups of patients. Figure 2 illustrates the changes in 
blood pressure in response to the 5 mg dose of amlodipine 
Figure 2 Changes in systolic (SBP) and diastolic (DBP) blood pressure induced by an 8-week treatment with amlodipine 5 mg and valsartan 160 mg, alone or in combination, 
compared with placebo, in patients with stage 1 and stage 2 hypertension.  Adapted with permission from Smith et al. J Clin Hypertens (Greenwich). 2007;9:355–364.29 Copyright 
© 2007 John Wiley & Sons, Inc.
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and 160 mg dose of valsartan, as mono- or combination 
therapy. At these doses, the two agents lowered blood pres-
sure by an average of 14.6/14.2 mmHg in stage 1 hyperten-
sion, compared with 23.2/13.9 mmHg in stage 2 hypertension 
(Study 1). The corresponding blood pressure reductions 
induced by combining 10 mg of amlodipine and 160 mg of 
valsartan averaged 20.3/16.5 mmHg and 29.6/17.6 mmHg, 
respectively (Study 2). The lowest doses commonly combined 
in everyday practice (amlodipine 5 mg and valsartan 80 mg) 
were also more effective in stage 2 (−24.2/−14.6 mmHg) than 
in stage 1 hypertension (−16.9/−13.9 mmHg).
Another issue is the influence of age on the blood 
pressure response to amlodipine and valsartan, alone or in 
combination. The patients enrolled in the two controlled 
trials reported by Smith and colleagues were divided in 
two subgroups, ie, the older (65 years or older; n = 704; 
baseline blood pressure = 160.2/98.6 mmHg)) and the 
younger (less than 65 years; n = 2451; baseline blood 
pressure =152.7/99.4 mmHg) patients.29 All active therapies 
produced greater blood pressure reductions than placebo. 
Figure 3 depicts the blood pressure changes induced by the 
5 mg amlodipine dose and 160 mg of valsartan dose, alone 
or in combination. Notably, both agents given alone were 
more effective in lowering blood pressure in older than 
in younger subjects. In the older patients, the response of 
systolic blood pressure to amlodipine was greater than the 
corresponding response to valsartan. The co-administration 
of the two agents decreased blood pressure to a similar 
Figure 3 Changes in systolic (SBP) and diastolic (DBP) blood pressure induced by an 8-week treatment with amlodipine 5 mg and valsartan 160 mg, alone or in combination, compared 
with placebo, in older and younger patients. Adapted with permission from Smith et al. J Clin Hypertens (Greenwich). 2007;9:355–364.29 Copyright © 2007 John Wiley & Sons, Inc.
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magnitude in the two age groups. Using the amlodipine 
10 mg valsartan/160 mg combination, blood pressure was 
reduced by 25.2/15.7 mmHg and 27.0/17.8 mmHg in the 
older and younger patients, respectively.
Ethnicity is another factor having the potential to 
influence the antihypertensive efficacy of amlodipine 
and valsartan. CAs are presumed to be more effective in 
black than in white patients and, conversely, ARBs more 
effective in white than in black patients.30 There were only 
few black patients (n = 201) included in the population 
pooled from 2 controlled trials by Smith and colleagues, 
precluding a direct meaningful comparison of the blood 
pressure responses between the two ethnic groups.29 
In both subgroups monotherapies were more effective than 
placebo, and combination therapies more effective than the 
corresponding component given alone.
Figure 4 illustrates the overall incidence of adverse events 
observed in patients allocated to amlodipine (n = 460) and 
valsartan (n = 921), their combination (n = 1437) or placebo 
(n = 337).29 Adverse events tended to be more frequent during 
Figure 4 Overall incidence of adverse events (AEs) with amlodipine and valsartan, alone or in combination, in patients with stage 1 or stage 2 hypertension (upper panel), and in 
younger or older patients (lower panel). Adapted with permission from Smith et al. J Clin Hypertens (Greenwich). 2007;9:355–364.29 Copyright © 2007 John Wiley & Sons, Inc.
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amlodipine therapy in stage 1 than in stage 2 hypertension 
(upper panel). Valsartan given alone had a placebo-like 
tolerability regardless of the degree of blood pressure elevation 
at baseline. Amlodipine combined with valsartan exhibited in 
both hypertension stages a tolerability comparable to that of 
amlodipine administered as single agent. Notably, tolerability 
was substantially better in older than in younger patients 
(lower panel). This was true whether the patients received 
an active treatment or placebo. Valsartan and placebo were 
equally well tolerated. In both age groups, the incidence of 
adverse events was very similar when amlodipine was given 
alone or together with valsartan. Thus, the common belief 
that older patients do not tolerate antihypertensive therapy as 
well as younger patients was not conﬁ rmed using amlodipine 
and valsartan.
Blockade of the renin-angiotensin 
system plus calcium entry blockade 
or diuretic therapy
Dual therapy with a blocker of the renin-angiotensin system 
and a CA represents today an important therapeutic option, 
similar to that based on a blocker of the renin-angiotensin 
and a thiazide diuretic.6 It is worth mentioning here a study 
aimed to compare the efﬁ cacy and the tolerability of 2 com-
bination regimens, one containing a CA (amlodipine) and 
an ARB (valsartan), and the other an ACE-I (lisinopril) 
and a diuretic (hydrochlorothiazide, HCTZ).31 The patients 
included in this trial had stage 2 hypertension, ie, patients 
in whom the use of a ﬁ xed-dose combination could be con-
sidered to initiate antihypertensive therapy.6,32 They were 
randomly allocated to receive for 6 weeks, according to a 
double-blind design, once-daily treatment with amlodipine 
5 mg and valsartan 160 mg (n = 63), or lisinopril 10 mg 
and HCTZ 12.5 mg (n = 65). The doses of amlodipine and 
lisinopril were increased to 10 mg and 20 mg, respectively, 
if diastolic blood pressure remained 90 mmHg after the 
ﬁ rst 2 weeks of treatment. There was no signiﬁ cant differ-
ence in the blood pressure reductions achieved at the end 
of the 6-week follow-up between the two drug regimens 
(amlodipine–valsartan: 35.8/28.6 mmHg; lisinopril–HCTZ: 
31.8/27.6 mmHg). Notably, both treatments were equally 
well tolerated.
The observations made by Poldermans and colleagues 
suggest that both types of combinations can be used 
indiscriminately in hypertensive patients, in terms both of 
antihypertensive efﬁ cacy and tolerability. One should keep 
in mind, however, that the trial was carried out according 
to a parallel-group design, which does not enable any 
conclusions to be drawn about individual responses. A given 
patient may normalize his/her blood pressure regardless of 
the content of the drug combination, or exclusively with one 
type of combination, or even be a non-responder to both 
combinations. The same is true for tolerability. Any drug 
combination might occasionally cause adverse events in a 
given patient. There is therefore still need for individualization 
of treatment when co-administering 2 antihypertensive 
agents with different mechanisms of action, the aim being 
to normalize blood pressure with no adverse impact on the 
patient’s quality of life.
The main mechanism of action of ARBs and ACE-Is 
is related to the blocking effect of these drugs on the 
renin-angiotensin system. It is possible, however, that 
some accumulation of kinins occurs during ACE inhibition, 
which might contribute to the blood pressure-lowering 
effect of ACE-I. Combining an ARB and an ACE-I 
therefore appears attractive, not only to achieve maximal 
blockade of the renin-angiotensin system, but also to gain 
in antihypertensive efﬁ cacy via a bradykinin-induced 
release of NO from the endothelium. A study was 
performed in 64 patients with an ambulatory blood pressure 
not controlled by valsartan, 160 mg/day, to compare the 
additional antihypertensive effects of the ACE-I benazepril, 
20 mg/day, the diuretic chlortalidone, 12.5 mg/day, or 
amlodipine, 5 mg/day.33 These three types of agents 
were administered on top of valsartan, 160 mg/day, for 
5-week periods. Combining valsartan and benazepril led 
to a signiﬁ cant additional decrease in 24-h ambulatory 
blood pressure (−8.6/−6.3 mmHg). This was, however, 
signiﬁ cantly less than the comparative 24-h ambulatory 
blood pressure reduction obtained by co-administering 
valsartan and amlodipine (−15.2/−9.9 mmHg) or valsartan 
and chlortalidone (−13.5/9.5 mmHg).
Another key issue is related to the potential impact of 
various combinations on cardiovascular and renal outcomes. 
An ACE-I (benazepril, 20–40 mg)-CA (amlodipine, 5–10 mg) 
combination (n = 5713) and a ACE-I (benazepril, 20–40 mg)–
diuretic (HCTZ, 12.5–25 mg) combination (n = 5733) have 
been directly compared recently in patients aged 55 years 
with either a systolic blood pressure 160 mmHg or cur-
rently on antihypertensive therapy. An additional inclusion 
criterion was the existence of cardiovascular, renal disease 
or other target organ damage.34 In this trial, known as the 
ACCOMPLISH Study (Avoiding Cardiovascular events 
through COMbination therapy in Patients Living with Sys-
tolic Hypertension), the aim was to lower blood pressure 
below 140 mmHg in most patients, and below 130/80 mmHg 
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in patients with diabetes or renal insufﬁ ciency. To this end 
the doses of the study drugs could be titrated within the ﬁ rst 
3 months, and additional antihypertensive agents added 
thereafter if required. The trial was stopped prematurely in 
March 2008 because of a signiﬁ cant lower cardiovascular 
mortality and morbidity in the benazepril–amlodipine group 
compared with the benazepril–HCTZ group (risk ratio [95% 
CI] = 0.80 [0.72–0.90]). The preliminary results of the 
ACCOMPLISH Study have been presented at the Annual 
Scientiﬁ c Sessions of the ACC, on March 31, 2008 by Profes-
sor Kenneth Jamerson in Chicago, USA. The blood pressure 
control rate at completion of the trial was high and comparable 
in the two groups (81.7% in the benazepril–amlodipine group 
and 78.5% in the benazepril–HCTZ group). The ﬁ nal results 
have been released very recently.35 The benazepril–amlo-
dipine drug regimen was found to reduce signiﬁ cantly the 
relative risk of developing events such as fatal and non-fatal 
myocardial infarction (−22%) and coronary revascularization 
(−14%), suggesting that this type of combination is particu-
larly effective in hypertensive patients for the prevention 
of complications caused by myocardial ischemia. These 
data are of great interest as the ACCOMPLISH Study is 
the ﬁ rst outcome trial to compare ﬁ xed-dose combinations. 
The subgroup analysis will tell us if some patients are more 
likely to beneﬁ t from an ACE-I-CA combination than from 
an ACE-I-HCTZ combination.
Perspectives
The increasing popularity of ﬁ xed-dose combinations in the 
treatment of hypertension is justiﬁ ed. Co-administering two 
antihypertensive agents with complementary mechanisms 
of action enables a better blood pressure control, but not 
at the expense of a deterioration in tolerability. Also, 
the simpliﬁ cation of treatment afforded by single tablets 
containing 2 active drugs facilitates long-term compliance with 
therapy, which is expected to affect positively cardiovascular 
and renal outcome. The ﬁ xed-dose combination based on a 
dihydropyridine CA and an ARB is a good example of an 
effective and well-tolerated ﬁ xed-dose combination. Such 
agents have no adverse metabolic impact and have been 
shown to have protective effects in large morbidity-mortality 
trials.3–6 It appears therefore more and more appealing to 
block at the same time the renin-angiotensin system and 
calcium channels in the vasculature.
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